BioNexus Gene Lab Aktie
WKN DE: A3D7PF / ISIN: US0906281086
20.10.2025 15:50:26
|
BioNexus Gene Lab Partners With BirchBioMed To Bring Clinically Validated Therapies To Asia
(RTTNews) - BioNexus Gene Lab Corp. (BGLC), Monday announced a non-binding Strategic Partnership Term Sheet with Canada-based BirchBioMed Inc. to bring clinically validated therapies to Asia in a capital-efficient manner.
As per the terms of the deal, BioNexus would lead Birch's $10 million upcoming financing round through a strategic equity investment and collaboration to accelerate commercialization of the latter's FS2 topical platform in Southeast Asia.
The collaboration aims to integrate BioNexus's regional market access and infrastructure with Birch's novel science in dermal regeneration and fibrosis control.
Currently, BGLC is moving down 5.95 percent, to $4.82 on the Nasdaq.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu BioNexus Gene Lab Corp Registered Shsmehr Nachrichten
Keine Nachrichten verfügbar. |